Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

2.560 -0.230 (-8.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about INmune Bio Inc. - Common stock

< Previous 1 2 3 4 5 6 7 Next >
Let's uncover which stocks are experiencing notable gaps during today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
What to Expect from INmune Bio's Earnings
 
Via Benzinga
INmune Bio Skyrockets After-Hours On Alzheimer’s Trial Buzz; Retail Bulls Bet Big Before Data Reveal Next Week
INmune is also developing XPro for treatment-resistant depression and exploring other immune-driven conditions like cancer and rare skin disorders. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Get insights into the top gainers and losers of Thursday's after-hours session.
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th
From INmune Bio, Inc.
Via GlobeNewswire
XPro™ Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer’s Disease: Supported by Department of Defense
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th
From INmune Bio, Inc.
Via GlobeNewswire
Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
From INmune Bio, Inc.
Via GlobeNewswire
Earnings Scheduled For March 27, 2025
 
Via Benzinga
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans
From INmune Bio, Inc.
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
C-Suite Buy of the Week: Executive Moves from Biotech to Banking
 
Via Benzinga
INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt
From INmune Bio, Inc.
Via GlobeNewswire
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
From OmniScience
Via Business Wire
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
From INmune Bio, Inc.
Via GlobeNewswire
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
From INmune Bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.